Page last updated: 2024-11-07

ad 5075

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID128440
CHEMBL ID88496
SCHEMBL ID131888
MeSH IDM0237745

Synonyms (20)

Synonym
CHEMBL88496
ad 5075
gtpl2701
gtpl2702
ad5075
[3h]ad5075
[3h]-ad5075
5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
5-(4-(2-(5-methyl-2-phenyl-4-oxazolyl)-2-hydroxyethoxy)benzyl)-2,4-thiazolidinedione
ad-5075
2,4-thiazolidinedione, 5-((4-(2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)-
103788-05-2
2,4-thiazolidinedione,5-[[4-[2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
SCHEMBL131888
[3h]ad-5075
YVQKIDLSVHRBGZ-UHFFFAOYSA-N ,
Q27074312
DTXSID00908597
4-hydroxy-5-({4-[2-hydroxy-2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl}methyl)-1,3-thiazol-2(5h)-one
AKOS040750125

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The effect of insulin sensitizer treatment on muscle insulin action was studied using ob/ob mice after 4 days dosing with a potent (6 nM PPARgamma Kd) TZD (10 mg/kg x day)."( Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action.
Berger, J; Doebber, T; Li, Z; McCrary, C; Moller, DE; Ryder, JW; Ventre, J; Woods, J; Wu, M; Zhang, B; Zierath, JR, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID136473Maximum reduction in plasma triglyceride levels in KKA mice at a dosage of 0.001% in diet1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents.
AID127973Effective dose to reduce 25% of glucose levels in blood1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents.
AID136474Maximum reduction in plasma triglyceride levels in KKA mice at a dosage of 0.005% in diet1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents.
AID127974Effective dose to reduce 25% of triglyceride levels in plasma1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents.
AID136470Maximum reduction in blood glucose levels in KKA mice at a dosage of 0.005% in diet1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents.
AID136469Maximum reduction in blood glucose levels in KKA mice at a dosage of 0.001% in diet1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents.
AID1346800Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors)1999The Journal of biological chemistry, Mar-05, Volume: 274, Issue:10
Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects.
AID1346800Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors)2003Molecular endocrinology (Baltimore, Md.), Apr, Volume: 17, Issue:4
Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator.
AID1346800Human Peroxisome proliferator-activated receptor-gamma (1C. Peroxisome proliferator-activated receptors)1996Endocrinology, Oct, Volume: 137, Issue:10
Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (88.89)18.2507
2000's1 (11.11)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.86 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]